KAR 5585

Drug Profile

KAR 5585

Alternative Names: KAR5585

Latest Information Update: 13 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Karos Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Serotonin modulators; Tryptophan hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pulmonary arterial hypertension
  • Preclinical Idiopathic pulmonary fibrosis

Most Recent Events

  • 17 Aug 2016 Karos Pharmaceuticals plans a phase II trial for Malignant carcinoid syndrome in 2017 in the USA
  • 17 Aug 2016 Karos Pharmaceuticals has patent protection for KAR 5585 in USA
  • 01 Aug 2016 Karos Pharmaceuticals completes a phase-I clinical trials in Pulmonary arterial hypertension (In volunteers) in USA (PO) (NCT02746237)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top